Health · Pharma & Biotech · 5 hrs ago
GLP-1 drugs may have a role in addiction care, but questions remain
GLP-1 receptor agonists are drugs best known for treating diabetes and obesity.
Researchers are exploring whether they could also help in addiction care.
A study published in March found that adults with Type 2 diabetes or obesity who used these drugs had 75% lower odds of having any substance use disorder.
This finding shows an association, not proof that the drugs prevent or treat addiction.
The study population was limited to adults with Type 2 diabetes or obesity.
More evidence is needed to clarify what role, if any, GLP-1 drugs should have in addiction care.
No next steps are specified.
GLP-1 receptor agonists may have a role in addiction care, though questions remain.
The drugs are best known for treating diabetes and obesity.
A study published in March found GLP-1 use was associated with 75% lower odds of any substance use disorder.
The study involved adults with Type 2 diabetes or obesity.
- Who
- Adults with Type 2 diabetes or obesity were included in the study.
- What
- A study found GLP-1 use was associated with 75% lower odds of any substance use disorder.
- When
- The study was published in March; the year is not stated.
- Where
- Not stated
- Why
- The sources do not state why GLP-1 use was associated with lower odds.
This story does not have two clearly opposing sides.
A study on GLP-1 use and substance use disorder was published.
Becker's Hospital Review published an article about unanswered questions on GLP-1 drugs in addiction care.
- Drug class
- GLP-1 receptor agonists
- Association
- 75% lower odds of any substance use disorder
- Study population
- Adults with Type 2 diabetes or obesity
- Publication date
- 2026-10-12
Sources
Related news
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
Lenacapavir and cabotegravir controlled HIV in a small patient study
EU approves evolocumab for adults at high cardiovascular risk
